Journal of Translational Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us 443308081224

Editorial - Journal of Translational Research (2017) Volume 0, Issue 0

The newest medicine: Chimeric antigen receptor T-Cell immunotherapy (CAR-T)

Recent approval of chimeric antigen receptor T-cell immunotherapy (CAR-T) for the clinical use represents a significant progress in the human defense war against cancer, and validates a novel bio-pharmaceutical platform that synergizes the strengths of adoptive cellular immunotherapy as well as molecular genetic engineering. With the curable efficacy for refractory B-cell malignancy, CAR-T is increasingly contributing to a paradigm shift toward immunotherapy in oncologic medicine and pharmaceutical innovation. Through optimization of the relevant bio-technological aspects with timely translation from science to medicine, CAR-T pipeline is expected to go beyond hematological application, to deliver additional therapeutic benefits to the patients with solid tumors.

Author(s): Daohong Chen

Abstract Full Text PDF

Get the App